Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Shelley McElhanon

Physician Assistant Charlotte, NC Physician Assistant

NPI 1548217300 CMS profile 10551332

10620 Park Rd, Suite 128, Charlotte, NC 28210

Open in the dashboard

General payments

$4,686

263 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Shelley McElhanon of Charlotte, NC is reported in the CMS Open Payments database as having received $4,686 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,460 74
2022 General $1,397 80
2021 General $1,830 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelley McElhanon
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Shelley McElhanon were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Shelley McElhanon Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,830 $132 $37–$438 $132
2022 $1,397 $155 $48–$522 $149
2023 $1,460 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Novo Nordisk Inc $1,027 59 payments
  2. AbbVie, Inc. $773 50 payments
  3. AstraZeneca Pharmaceuticals LP $574 17 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $285 14 payments
  5. Pfizer Inc. $235 19 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $197 12 payments
  7. Lilly USA, LLC $172 12 payments
  8. Biohaven Pharmaceuticals, Inc. $155 10 payments
  9. Merck Sharp & Dohme Corporation $149 9 payments
  10. Amarin Pharma Inc. $143 10 payments
  11. Other $977 51 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $4,685 262 payments
  2. Education $1 1 payment
Products named General payments · program years 2021–2023
  1. RYBELSUS $628 36 payments
  2. Ozempic $460 32 payments
  3. FARXIGA $402 13 payments
  4. UBRELVY $330 21 payments
  5. Wegovy $270 11 payments
  6. NURTEC ODT $249 15 payments
  7. VRAYLAR $230 16 payments
  8. TRINTELLIX $213 11 payments
  9. XIFAXAN $197 12 payments
  10. BREZTRI $171 4 payments
  11. Other $2,792 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

2,094

Median for Physician Assistant: 241

Drug cost

$73,841

Median for Physician Assistant: $4,110

Branded share of claims

13.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 14 $18,696
Xarelto Rivaroxaban Brand 11 $17,530
Eliquis Apixaban Brand 19 $14,442
Gabapentin Generic 103 $1,775
Omeprazole Generic 122 $1,538
Fluoxetine Hcl Generic 111 $1,366
Levothyroxine Sodium Generic 140 $1,352
Synthroid Levothyroxine Sodium Brand 13 $1,302
Atorvastatin Calcium Generic 147 $973
Rosuvastatin Calcium Generic 97 $960

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record